[go: up one dir, main page]

PL2214480T3 - Sposoby leczenia niealkoholowego stłuszczającego zapalenia wątroby (NASH) przy użyciu produktów cysteaminowych - Google Patents

Sposoby leczenia niealkoholowego stłuszczającego zapalenia wątroby (NASH) przy użyciu produktów cysteaminowych

Info

Publication number
PL2214480T3
PL2214480T3 PL08853916T PL08853916T PL2214480T3 PL 2214480 T3 PL2214480 T3 PL 2214480T3 PL 08853916 T PL08853916 T PL 08853916T PL 08853916 T PL08853916 T PL 08853916T PL 2214480 T3 PL2214480 T3 PL 2214480T3
Authority
PL
Poland
Prior art keywords
nash
methods
alcoholic steatohepatitis
treating non
cysteamine products
Prior art date
Application number
PL08853916T
Other languages
English (en)
Inventor
Ranjan Dohil
Jerry Schneider
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2214480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PL2214480T3 publication Critical patent/PL2214480T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL08853916T 2007-11-30 2008-11-28 Sposoby leczenia niealkoholowego stłuszczającego zapalenia wątroby (NASH) przy użyciu produktów cysteaminowych PL2214480T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31
EP08853916A EP2214480B1 (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
PCT/US2008/085064 WO2009070781A1 (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Publications (1)

Publication Number Publication Date
PL2214480T3 true PL2214480T3 (pl) 2013-11-29

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08853916T PL2214480T3 (pl) 2007-11-30 2008-11-28 Sposoby leczenia niealkoholowego stłuszczającego zapalenia wątroby (NASH) przy użyciu produktów cysteaminowych

Country Status (25)

Country Link
US (5) US7994226B2 (pl)
EP (2) EP2636404B1 (pl)
JP (3) JP5583022B2 (pl)
KR (1) KR20100091219A (pl)
CN (2) CN101932238B (pl)
AR (1) AR069500A1 (pl)
AU (1) AU2008329628B2 (pl)
BR (1) BRPI0819690B8 (pl)
CA (1) CA2706768C (pl)
CL (1) CL2008003582A1 (pl)
CY (1) CY1114126T1 (pl)
DK (1) DK2214480T3 (pl)
ES (1) ES2417179T3 (pl)
HR (1) HRP20130590T1 (pl)
IL (2) IL205909B (pl)
MX (2) MX360827B (pl)
MY (1) MY156316A (pl)
NZ (1) NZ585732A (pl)
PL (1) PL2214480T3 (pl)
PT (1) PT2214480E (pl)
RU (1) RU2498795C2 (pl)
SG (1) SG10201403200RA (pl)
TW (2) TWI478710B (pl)
WO (1) WO2009070781A1 (pl)
ZA (1) ZA201003670B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640531C (en) 2006-01-27 2017-01-03 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
AU2008329628B2 (en) * 2007-11-30 2014-06-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
US20130066075A1 (en) * 2010-05-19 2013-03-14 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
US20110300190A1 (en) * 2010-06-08 2011-12-08 Krisani Biosciences (P) Ltd Compound, composition and uses thereof
CN103108634B (zh) * 2010-07-28 2015-08-12 幽兰化学医药有限公司 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130085075A1 (en) * 2011-06-06 2013-04-04 Meso Scale Technologies, Llc Diagnostic methods for liver disorders
US8658787B2 (en) 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
AU2011379972B2 (en) * 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
MX2014004469A (es) * 2011-11-22 2014-08-01 Univ California Metodos y composiciones para tratar inflamacion y lesion isquemica.
HK1206646A1 (en) * 2012-03-29 2016-01-15 Halo Therapeutics, Llc Dosage forms of halofuginone and methods of use
AU2013271585B2 (en) 2012-06-06 2018-02-01 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CN113967215A (zh) * 2014-04-18 2022-01-25 Lg 化学株式会社 用于预防或治疗脂肪肝疾病的组合物
BR112017018882A2 (pt) * 2015-03-03 2018-04-17 Kohjin Life Sciences Co Ltd composição para aperfeiçoamento ou prevenção de uma doença de fígado gorduroso não alcoólico
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
KR102414503B1 (ko) 2016-03-17 2022-06-29 티오제네시스 테라퓨틱스, 인크. 시스테아민의 조절 방출을 위한 조성물 및 시스테아민 민감성 장애의 전신 치료
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
JP7270979B2 (ja) * 2017-06-08 2023-05-11 エヌ－ジーン リサーチ ラボラトリーズ，アイエヌシー． Ｎａｓｈ治療方法及びｎａｓｈ誘発性ｈｃｃ予防方法
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
US11612576B2 (en) 2017-09-20 2023-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
WO2020198529A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
CA3143834A1 (en) * 2019-07-19 2021-01-28 Xiyan LI Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
CN118489805A (zh) * 2024-05-31 2024-08-16 杭州康德权饲料有限公司 半胱胺或其盐在制备预防和改善蛋鸡脂肪肝的饲料添加剂中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030137125A1 (en) * 2000-02-14 2003-07-24 Len Booysen Stabilizer unit
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
AU2002352982B2 (en) * 2001-11-29 2008-03-06 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
ES2497716T3 (es) * 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
WO2005049002A1 (en) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
MXPA06007100A (es) 2003-12-19 2007-01-19 Omega Bio Pharma Ip3 Ltd Composiciones y metodos para tratar la diabetes.
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
JP4976281B2 (ja) * 2004-05-03 2012-07-18 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 代謝を調節するための材料および方法
EP1844006A2 (en) 2005-01-05 2007-10-17 Magd Ahmed Kotb Abdalla Taurine synthesis, production and utility as a medicine
AU2006236150A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
CA2640531C (en) 2006-01-27 2017-01-03 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
WO2007121545A1 (en) 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US20090304704A1 (en) 2006-05-03 2009-12-10 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
WO2008093764A1 (ja) 2007-02-02 2008-08-07 Kaneka Corporation 糖尿病予防または治療用組成物
AU2008329628B2 (en) * 2007-11-30 2014-06-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

Also Published As

Publication number Publication date
DK2214480T3 (da) 2013-07-08
AU2008329628B2 (en) 2014-06-26
TWI478710B (zh) 2015-04-01
KR20100091219A (ko) 2010-08-18
TW201513855A (zh) 2015-04-16
TW200927093A (en) 2009-07-01
US9149448B2 (en) 2015-10-06
IL254586A0 (en) 2017-11-30
US10307386B2 (en) 2019-06-04
IL205909A0 (en) 2010-11-30
US20160143865A1 (en) 2016-05-26
SG10201403200RA (en) 2014-10-30
EP2636404A3 (en) 2013-10-16
EP2636404A2 (en) 2013-09-11
EP2214480A1 (en) 2010-08-11
EP2214480B1 (en) 2013-03-27
CY1114126T1 (el) 2016-07-27
PT2214480E (pt) 2013-07-23
JP2014237670A (ja) 2014-12-18
US8263662B2 (en) 2012-09-11
RU2010126631A (ru) 2012-01-10
CA2706768C (en) 2016-06-28
US9511038B2 (en) 2016-12-06
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
CL2008003582A1 (es) 2009-04-03
US20130183351A1 (en) 2013-07-18
MX2010005921A (es) 2010-06-11
ZA201003670B (en) 2011-08-31
US20170304233A1 (en) 2017-10-26
JP2011505375A (ja) 2011-02-24
US7994226B2 (en) 2011-08-09
JP2017165735A (ja) 2017-09-21
CN101932238A (zh) 2010-12-29
BRPI0819690B8 (pt) 2021-05-25
AU2008329628A1 (en) 2009-06-04
MX360827B (es) 2018-11-16
JP5583022B2 (ja) 2014-09-03
MY156316A (en) 2016-02-11
CA2706768A1 (en) 2009-06-04
CN101932238B (zh) 2015-04-08
HRP20130590T1 (en) 2013-08-31
ES2417179T3 (es) 2013-08-06
BRPI0819690B1 (pt) 2019-07-30
TWI535435B (zh) 2016-06-01
HK1141945A1 (en) 2010-11-26
WO2009070781A1 (en) 2009-06-04
NZ585732A (en) 2012-02-24
RU2498795C2 (ru) 2013-11-20
JP6121951B2 (ja) 2017-04-26
AR069500A1 (es) 2010-01-27
IL205909B (en) 2018-05-31
EP2636404B1 (en) 2019-03-20
US20100303870A1 (en) 2010-12-02
EP2214480A4 (en) 2010-09-29
BRPI0819690A2 (pt) 2014-10-07
US20120015005A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
IL254586A0 (en) Methods for treating NASH using cystamine products
IL257681A (en) Methods and compositions for the treatment of cancer
PL2200431T3 (pl) Nowe kompozycje i metody służące leczeniu raka
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
PT2340042E (pt) Métodos e composições para o tratamento de cancro
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
PL2268292T3 (pl) Sposób i kompozycje do leczenia raka
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
EP2244690A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND DRESSES
ZA201008201B (en) Novel compositions and methods for treating hyperproliferative diseases
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
IL199689A0 (en) Compounds and method for treatment of cancer
GB0718918D0 (en) Compositions and methods for treating skin conditions
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
GB2445651B (en) Well treatment products and methods of using them
GB0605247D0 (en) Compositions and methods for immunisation
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
IL226363A0 (en) Compounds and methods for treating cancer
SI2214480T1 (sl) Postopki za zdravljenje nealkoholnega steatohepatitisa (NASH) z uporabo cisteaminskih proizvodov
IL196727A0 (en) Composition and method for treatment of tumors
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
LT3067054T (lt) Naujos kompozicijos ir būdai vėžiui gydyti